Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Medivir AB's enterprise value is kr1,074.85 Mil.
Medivir AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was kr-55.70 Mil. Therefore, Medivir AB's EV-to-EBITDA for today is -19.30.
The historical rank and industry rank for Medivir AB's EV-to-EBITDA or its related term are showing as below:
LTS:0GP7'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.3 Med: -2.31 Max: 0.15
Current: -19.3
During the past 13 years, the highest EV-to-EBITDA of Medivir AB was 0.15. The lowest was -19.30. And the median was -2.31.
LTS:0GP7's EV-to-EBITDA is ranked worse than 100% of 408
companies
in the Biotechnology industry
Industry Median: 14.13
vs LTS:0GP7: -19.30
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medivir AB's share price for today is kr1.9013.
Medivir AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.380.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Medivir AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0GP7 vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Medivir AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medivir AB EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medivir AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medivir AB's EV-to-EBITDA falls into.
Medivir AB's current Enterprise Value is kr1,074.85 Mil.
Medivir AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-55.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medivir AB (LTS:0GP7) has a EV-to-EBITDA of -19.30 as of Aug. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medivir AB. According to the industry distribution chart, Medivir AB ranks #999999 out of 408 companies in the Biotechnology industry.
Is Medivir AB's EV-to-EBITDA too high?
Medivir AB's current EV-to-EBITDA is -19.30. Based on the distribution chart, Medivir AB ranks #999999 out of 408 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medivir AB has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medivir AB ranks #999999 out of 408 companies for EV-to-EBITDA. This places Medivir AB in the lower half of its industry. The industry median EV-to-EBITDA is 14.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.13, based on 408 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medivir AB. For the Biotechnology industry, the median EV-to-EBITDA is 14.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medivir AB's current EV-to-EBITDA is -19.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (LTS:0GP7) is currently considered Significantly Overvalued. The stock's GF Value™ is kr1.01, compared to a current price of kr1.90 — trading 88.2% above its estimated fair value. The current EV-to-EBITDA is -19.30. Medivir AB's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Medivir AB (LTS:0GP7), the current EV-to-EBITDA is -19.30 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medivir AB (LTS:0GP7) Overvalued in 2026?
Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued.
The current stock price of kr1.90 is trading 88.2% above its estimated GF Value™ of kr1.01.
GuruFocus considers Medivir AB to be Significantly Overvalued.
Key valuation signals for LTS:0GP7:
EV-to-EBITDA: -19.30
GF Value™: kr1.01 vs. price of kr1.90 (88.2% above fair value)
No single metric tells the full story. See the LTS:0GP7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
44GF Score
Get the complete analysis for LTS:0GP7
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0GP7 has been successfully added to your 
